{"id":908813,"date":"2025-11-12T10:35:52","date_gmt":"2025-11-12T15:35:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-reports-updated-clinical-results\/"},"modified":"2025-11-12T10:35:52","modified_gmt":"2025-11-12T15:35:52","slug":"neonc-technologies-reports-updated-clinical-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-reports-updated-clinical-results\/","title":{"rendered":"NeOnc Technologies Reports Updated Clinical Results"},"content":{"rendered":"

\nResults of Clinical Trials Provide Evidence Supporting Significant Radiographic Response and Potential Long-Term Survival in Recurrent Grade III\/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100
\n<\/h2>\n
\n

CALABASAS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (\u201cNeOnc\u201d or the \u201cCompany\u201d)<\/strong>, a multi\u2013Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers today announced updated clinical results from its current Phase 1\/2a and compassionate care studies involving a cohort of 24 patients with recurrent WHO Grade III\/IV isocitrate dehydrogenase 1 (IDH1)\u2013mutant astrocytoma treated with its investigational intranasal agent, NEO100.<\/p>\n

Clinical results provided support that treatment with intranasally delivered NEO100 resulted in a significant radiographic response, confirmed by contrast-enhanced and perfusion MRI, in 5 of 24 patients (21%)\u2014a rate that markedly exceeds the <8% response typically observed with salvage therapies for recurrent gliomas. Additionally, results indicated that 44% of patients in this Phase 2a study achieved six-month progression-free survival (PFS-6), surpassing the 21\u201331% benchmark reported in historical datasets for IDH1-mutant recurrent high-grade gliomas. Furthermore, 8 of 24 patients (33%) remained alive \u226518 months after initiation of NEO100, demonstrating long term survival.<\/p>\n

In addition, no significant toxicity was reported with intranasal administration of NEO100, even with prolonged, chronic intranasal administration, underscoring its potential utility as a therapeutic option for this patient population.<\/p>\n

Amir F. Heshmatpour, Executive Chairman, President & CEO of NeOnc Technologies Holdings, Inc., stated: \u201cWith these data, we believe NeOnc stands at the threshold of a true game-changer for one of medicine\u2019s greatest unmet needs\u2014recurrent IDH1-mutant hi grade gliomas. For the first time, we\u2019re witnessing evidence of meaningful radiographic responses and support for durable survival in patients who previously had few, if any, options. As we approach full enrollment of the NEO100 trial\u2014and our full data readout six months post-enrollment\u2014we believe this may represent a potential paradigm shift in the treatment of brain cancer. The data will speak for itself\u2014and for the patients whose lives we are determined to transform.\u201d<\/p>\n

Mr. Heshmatpour added: \u201cWe view this trial as a pivotal value inflection point for NeOnc and for the broader neuro-oncology field signaling a potential move beyond palliation toward measurable, durable disease control and a possible new standard of care in malignant gliomas.\u201d<\/p>\n

Founder, Dr. Thomas Chen, Vice-Chairman and Chief Medical Officer noted that, \u201cThe data suggest that intranasal NEO100 may be the first central nervous system (CNS)\u2013penetrant metabolic therapy capable of inducing durable response and multi-year survival in recurrent IDH1 mutant gliomas.”<\/p>\n

Dr. Henry Friedman of Duke University emphasized the implications of these findings, stating, \u201cThe results from NEO100 signify a potential paradigm shift in the treatment of recurrent IDH1-mutant gliomas.\u201d<\/p>\n

Key Data Highlights:<\/p>\n